Pharmacokinetic and pharmacodynamic concepts for an interpretative reading of the antibiogram;Aspectos farmacocinéticos y farmacodinámicos para la lectura interpretada del antibiograma

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 20, Issue 8, 2002, Pages 407-412

  Soriano, Francisco ^a,b  

^a Hospital UniversitarioFundación Jiménez Díaz   (Spain)

^b Fund Jiménez Díaz   (Spain)

Author keywords

Antibiogram; Pharmacodynamics; Pharmacokinetics

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CLARITHROMYCIN; CLINDAMYCIN; DALFOPRISTIN PLUS QUINUPRISTIN; ERYTHROMYCIN; GLYCOPEPTIDE; LINEZOLID; METRONIDAZOLE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TELITHROMYCIN; TETRACYCLINE DERIVATIVE; ZIDOVUDINE;

ANTIBIOTIC SENSITIVITY; ARTICLE; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG METABOLISM; MICROBIOLOGICAL EXAMINATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN;

EID: 0346605926     PISSN: 0213005X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0213-005X(02)72829-2     Document Type: Article

References (30)

1. Soriano F. Optimal dosage of β-lactam antibiotics: Time above the MIC and inoculum effect (leading article). J Antimicrob Chemother 1992;30:566-9.
2. Soriano F, García-Corbeira P, Ponte C, Fernández-Roblas R, Gadea I. Correlation of pharmacodynamic parameters of five β-lactam antibiotics with therapeutic efficacy in an animal model. Antimicrobial Agents Chemother 1996;40:2686-90.
3. Drusano GL, Goldstein FW. Relevance of the Alexander Project: Pharmacodynamic considerations. J Antimicrob Chemother 1996;38(Suppl A): 141-54.
4. Soriano F, Fernández-Roblas R. Criterios de susceptibilidad antibacteriana in vitro. Enferm Infecc Microbiol Clin 1995;13:173-5.
5. Pallarés R, Liñares J, Vadillo M, Cabellos C, Manresa F, Viladrich PF, et al. Resistance to penicillin and cephalosporin and mortality from severe penumococcal pneumonia in Barcelona, Spain. N Engl J Med 1995;333:474-80.
6. Viladrich PF, Gudiol F, Liñares J, Rufi G, Ariza J, Pallarés R. Characteristics and antibiotic therapy of adult meningitis due to penicillin-resistant pneumococci. Am J Med 1988;84:839-46.
7. Viladrich PF, Cabellos C, Pallarés R, Tubau F, Martínez-Lacasa J, Liñares J, et al. High doses of cefotaxime in treatment of adult meningitis due to Streptococcus pneumoniae with decreased susceptibilities to broad-spectrum cephalosporins. Antimicrob Agents Chemother 1996;40:218-20.
8. Davies BI, Maesen FP, Gubbelmans R. Azithromycin (CP-62,993) in acute exacerbations of chronic bronchitis: An open clinical, microbiological and pharmacokinetic study. J Antimicrob Chemother 1989;23:743-51.
9. Dagan R, Leibovitz E, Fliss DM, Leiberman A, Jacobs MR, Craig W, et al. Bacteriologic efficacies of oral azithromycin and oral cefaclor in treatment of acute otitis media in infants and young children. Antimicrob Agents Chemother 2000;44:43-50.
10. Tran JQ, Ballow CH, Forrest A, Hyatt JM, Sands MF, Peloquin CA, et al. Comparison of the abilities of grepafloxacin and clarithromycin to eradicate potential bacterial pathogens from the sputa of patients with chronic bronchitis: Influence of pharmacokinetic and pharmacodynamic variables. J Antimicrob Chemother 2000;45:9-17.
11. Craig WA, Vogelman B. Changing concepts and new applications of antibiotic pharmacokinetics. Am J Med 1984;77:24-8.
12. Craig WA. Pharmacokinetic/Pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998;26:1-12.
13. Soriano F. Selección de bacterias resistentes a los antimicrobianos: factores microbiológicos y farmacológicos. Med Clin 2001;117:632-6.
14. Shah PM, Junghanns W, Stille W. Dosis-Wirkungs-Beziehung der Bakterizidie bei E.coli, K.pneumoniae und Staphylococcus aureus. Dtsch Med Wochenschr 1976;101:325-8.
15. Craig WA. Post-antibiotic effects in experimental infection models: Relationship to in vitro phenomena and to treatment of infections in man. J Antimicrob Chemother 1993;31(Suppl D):149-58.
16. Fantin B, Ebert S, Leggett J, Vogelman B, Craig WA. Factors affecting duration of in-vivo postantibiotic effect for aminoglycosides against gram-negative bacilli. J Antimicrob Chemother 1991;27:829-36.
17. Moore RD, Lietman PS, Smith CR. Clinical response to aminoglycoside therapy: Importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis 1987;155:93-9.
18. Forrest A, Nix DE, Balow CH, Goss TF, Birmingham MC, Schentag JJ. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 1993;37:1073-81.
19. Soriano F. Lectura farmacodinámica de la susceptibilidad antibiótica a Streptococcus pneumoniae. Med Clin 1999;113:103-8.
20. Soriano F. Dosificación ideal y pauta de administración de los antibióticos betalactámicos orales en el tratamiento de la infección neumocócica. Enferm Infecc Microbiol Clin 1993;11(Suppl 1):44-50.
21. Lacy MA, Lu W, Xu X, Tessier PR, Nicolau P, Quintiliani R, et al. Pharmacodynamic comparisons of levofloxacin, ciprofloxacin, and ampicillin against Streptococcus pneumoniae in an in vitro model of infection. Antimicrob Agents Chemother 1999;43:672-7.
22. Craig WA. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. Diagn Microbiol Infect Dis 1995;22:89-96.
23. Craig WA, Andes D. Pharmacokinetics and pharmacodynamics of antibiotics in otitis media. Pediatr Infect Dis J 1996;15:255-9.
24. Klein JO. Microbiological efficacy of antibacterial drugs for acute otitis media. Pediatr Infect Dis J 1993;12:973-5.
25. Baquero F, Martínez-Beltrán J, Cantón R, Grupo MENSURA. Criterios del grupo MENSURA para la definición de los puntos criticos de sensibilidad a los antibióticos. Rev Esp Quimiot 1997;10:303-13.
26. Working Party of the British Society for Antimicrobial Chemotherapy. A guide to sensitivity testing. J Antimicrob Chemother 1991;27(Suppl D): 1-47.
27. Soussy CJ, Cluzel R, Courvalin O, and the Comité de l'Antibiogramme de la Société Française de Microbiologie. Definition and determination of in vitro antibiotic susceptibility breakpoints for bacteria in France. Eur J Clin Microbiol Infect Dis 1994;13:238-46.
28. National Committee for Clinical Laboratory Standards. 2001.Performance standards for antimicrobial susceptibility testing; eleventh informational supplement. Vol 21, number 1, M100-S11. Wayne, Pennsylvania, USA.
29. Olsson-Liljequist, Forsgren A. Antimicrobial susceptibility testing in Sweden. I. The work of the Swedish reference group for antibiotics (SRGA and SRGA-M). Scand J Infect Dis 1997;(Suppl)105:5-7.
30. Williams JD. BSAC guidelines on sensitivity testing. J Antimicrob Chemother 1993;31:1001-3.